Orange Book Listings Lesson: An overly broad use code may lead to legal challenges

Posted 23 July 2012 By Jane Wright-Mitchell, PharmD, JD

The US Supreme Court's recent Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S decision highlights the different viewpoints of the courts in the pharmaceutical arena, in particular drawing attention to the interaction of pharmaceutical patents to the US Food and Drug Administration (FDA)-generated Orange Book.

Share this article:

Categories: FDA

Tags: Caraco Pharmaceuticals, Orange Book, Novo Nordisk, Court, SCOTUS, ANDA, It's the Law, decision, legal

Regulatory Exchange: Latest Updates From the Community